3-bromo-5,22,23-trihydroxystigmastan-6-one: has antiherpetic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6479887 |
| CHEMBL ID | 239019 |
| SCHEMBL ID | 16593555 |
| MeSH ID | M0477689 |
| Synonym |
|---|
| (3s,5r,8s,9s,10r,13s,14s,17r)-3-bromo-17-[(1s,2s,3s,4s)-4-ethyl-2,3-dihydroxy-1,5-dimethyl-hexyl]-5-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-6-one |
| (22s,23s)-3-.beta.-bromo-5-.alpha.-22,23-trihydroxystigmastan-6-one |
| 188127-65-3 |
| CHEMBL239019 |
| (3s,5r,8s,9s,10r,13s,14s,17r)-3-bromo-17-[(2s,3s,4s,5s)-5-ethyl-3,4-dihydroxy-6-methylheptan-2-yl]-5-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-6-one |
| (22s,23s)-3-beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one |
| SCHEMBL16593555 |
| (22s,23s)-3beta-bromo-5alpha,22,23-trihydroxy-stigmastan-6-one |
| DTXSID50940306 |
| 3-bromo-5,22,23-trihydroxystigmastan-6-one |
| (1r,3as,3bs,5ar,7s,9ar,9bs,11as)-7-bromo-1-[(2s,3s,4s,5s)-5-ethyl-3,4-dihydroxy-6-methylheptan-2-yl]-5a-hydroxy-9a,11a-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-5-one |
| (3beta,5alpha,22s,23s)-3-bromo-5,22,23-trihydroxystigmastan-6-one |
| 3-bromo-5,22,23-trihydroxystigmastan-6-one, (3beta,5alpha,22s,23s)- |
| WA3VAC84QS |
| stigmastan-6-one, 3-bromo-5,22,23-trihydroxy-, (3beta,5alpha,22s,23s)- |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID302098 | Inhibition of LPS-induced TNFalpha production in mouse J774A.1 cells | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24 | Syntheses of immunomodulating androstanes and stigmastanes: comparison of their TNF-alpha inhibitory activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||